Carbapenem-resistant Klebsiella pneumoniae bloodstream infections: retrospective analysis

Abstract

Bloodstream infections caused by carbamazepine-resistant Klebsiella pneumoniae (CR-CR) are a serious clinical problem worldwide. The main problem in the treatment of bloodstream infections is the search for effective antibiotic treatment regimens, since carbapenem resistance, Klebsiella pneumoniae, as a rule, has associated resistance to many non-ß-lactam antibiotics, and the bloodstream infections caused by them are accompanied by high attributable mortality. Recent studies have shown that high-dose carbapenem, extended meropenem infusion, and additional drugs such as aminoglycosides and colistin warrant investigation to increase treatment efficacy. In addition, there is evidence that the use of carbapenems in combination with other active agents may reduce mortality, especially when strains have low levels of resistance to these antimicrobials in vitro. Moreover, a number of reports indicate that combination therapy is often more effective than monotherapy. Despite the promising prospects of combination therapy, challenges remain in finding optimal and effective treatment regimens. This study highlights the complexity of controlling bloodstream infections and highlights the need to find optimal strategies for their therapy